Affiliation:
1. Department of Chemical Pathology St Thomas' Hospital London
Abstract
SUMMARYHyperlipidaemia is acknowledged as the major risk factor for coronary heart disease and atheroma progression. This review considers the strategies that should be followed to reduce overall cardiovascular risk in patients with hyperlipidaemia and deals with the identification and management of treating both polygenic and monogenic lipid disorders in the presence or absence of overt cardiovascular disease.
Reference60 articles.
1. Serum Cholesterol, Lipoproteins, and the Risk of Coronary Heart Disease
2. Serum Cholesterol, Blood Pressure, Cigarette Smoking, and Death From Coronary Heart Disease Overall Findings and Differences by Age for 316099 White Men
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. (4S);Scandinavian Simvastatin Survival Study Group;Lancet,1994
4. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
5. Primary and secondary prevention of coronary heart disease by cholesterol reduction. Recent clinical trial data;McMurray JJV;Br J Cardiol,1996